Dohi T, Nakamura K, Hanai N, Taomoto K, Oshima M
Division of Biochemistry and Nutrition, International Medical Center of Japan, Tokyo.
Anticancer Res. 1994 Nov-Dec;14(6B):2577-81.
With the aim of investigating the passive immunotherapy of brain tumors, we examined the binding of a mouse/human chimeric anti-ganglioside GM2 antibody KM966 to various organs and brain tumors. Frozen sections of 51 surgically resected brain tumors were stained with antibody KM966. Fourteen gliomas out of 16 were stained positively with antibody KM966. Eleven positive sections demonstrated homogenous staining. No specific binding to normal gray matter and white matter was observed. Some cases of meningiomas, neurinomas and metastatic brain tumors were stained with KM966 but with less frequency and intensity than gliomas. In addition, KM966 demonstrated strong antibody-dependent cellular cytotoxicity against human malignant glioma cells. These results showed that antibody KM966 will be useful for passive immunotherapy of malignant gliomas.
为了研究脑肿瘤的被动免疫疗法，我们检测了小鼠/人嵌合抗神经节苷脂GM2抗体KM966与各种器官及脑肿瘤的结合情况。对51例手术切除的脑肿瘤冰冻切片用抗体KM966进行染色。16例胶质瘤中有14例被抗体KM966阳性染色。11张阳性切片显示染色均匀。未观察到与正常灰质和白质的特异性结合。部分脑膜瘤、神经鞘瘤和脑转移瘤病例可被KM966染色，但染色频率和强度低于胶质瘤。此外，KM966对人恶性胶质瘤细胞表现出强烈的抗体依赖性细胞毒性。这些结果表明，抗体KM966将有助于恶性胶质瘤的被动免疫治疗。
